GeoVax Labs Inc. is a clinical-stage biotechnology company. It engages in developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle based vaccine platform. GeoVax Labs Inc. is based in ATLANTA, GA.
| Revenue (Most Recent Fiscal Year) | $2.49M |
| Net Income (Most Recent Fiscal Year) | $-21.47M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.34 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -743.64% |
| Return on Assets (Trailing 12 Months) | -394.74% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.54 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.54 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.21 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.97 |
| Earnings per Share (Most Recent Fiscal Year) | $-22.40 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 7.37M |
| Free Float | 7.35M |
| Market Capitalization | $2.36M |
| Average Volume (Last 20 Days) | 0.25M |
| Beta (Past 60 Months) | 3.69 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.22% |
| Percentage Held By Institutions (Latest 13F Reports) | 6.09% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |